Title of Invention	CONTROL OF ARTHROPODS IN ANIMALS
Abstract	A 1 -arylpyrazole of formula (XX): (XX) Wherein: R201 is cyano; R202 is S(O)hR203; R203 is alkyl or haloalkyl; R204 is —N(R205)C(O)CR206 R207 R208; R205 is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, cycloalkylalkyl or halocycloalkylalkyl; R206 is alkoxy, haloalkoxy, alkoxyalkyl or haloalkoxy-alkyl; R207 and R208 are each hydrogen; Xi is nitrogen or C-R212; R211 and R212are, independently, halogen, hydrogen, CN or NO2; R213 is halogen, haloalkyl, haloalkoxy, -S(0)kCF3, or -SF5; and h and k are, independently, 0, 1 or 2; or a veterinarily acceptable salt thereof.

Title of Invention

CONTROL OF ARTHROPODS IN ANIMALS

Abstract

A 1 -arylpyrazole of formula (XX): (XX) Wherein: R201 is cyano; R202 is S(O)hR203; R203 is alkyl or haloalkyl; R204 is —N(R205)C(O)CR206 R207 R208; R205 is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, cycloalkylalkyl or halocycloalkylalkyl; R206 is alkoxy, haloalkoxy, alkoxyalkyl or haloalkoxy-alkyl; R207 and R208 are each hydrogen; Xi is nitrogen or C-R212; R211 and R212are, independently, halogen, hydrogen, CN or NO2; R213 is halogen, haloalkyl, haloalkoxy, -S(0)kCF3, or -SF5; and h and k are, independently, 0, 1 or 2; or a veterinarily acceptable salt thereof.

Full Text	FORM 2 THE PATENTS ACT 1970 [39 OF 1970] COMPLETE SPECIFICATION [See Section 10] "CONTROL OF ARTHROPODS IN ANIMALS" AVENTIS CROPSCIENCE S.A., a French body corporate of 55 Avenue Rene Cassin, F-69006 Lyon, France, The following specification particularly describes the nature of the invention and the manner in which it is to be performed :- Control of Arthropods in Animals The present invention relates to a method of control of parasites in animals, compositions comprising a compound effective for the said control and new compounds effective against parasites. It is generally a goal of agronomists and veterinarians to possess sufficient means to control pests, particularly arthropods, when they attempt to invade or attack mammals, particularly domestic animals and/' or livestock. A classical method of controlling such pests has been the use of topical and/or systemic pesticides on or in the domestic animal which is being attacked. Generally effective treatments include the oral administration of insect growth regulators, such as lufenuron, or antihelminth compounds such as an ivermectin or an avermectin, or the topical application of the insecticide fipronil. It is advantageous to apply pesticides to animals in oral form so as to prevent the possible contamination of humans or the surrounding environment. It is an object of the present invention to provide new pesticides which may be used in domestic animals. Another object of the invention is to provide safer pesticides for domestic animals. Another object of the invention is to provide new pesticides for domestic animals that may be used in lower doses than existing pesticides. These objects are met in whole or in part by the present invention. The present invention provides a method of controlling parasites in or on an animal comprising admini ferine orally to the animal a parasiticidally effective, substantially non-emetic amount of a 1-arylpyrazole of formula (I): WO 00/35884 PCT/EP99/10452 wherein: R\ is cyano, acetyl, C(S)NH2, alkyl, haloalkyl, C(=NOH)NH2 or C(=NNH2)NH2; R.2 is S(0)nR3; C2-C3 alkenyl, C2-C3 haloalkenyl, cycloalky], halocycloalkyl or C2-C3 alkynyl; R3 is alkyl or haloalkyl; R4 is -N=C(R5)-Z-R^, -N=C(R5)-N(R7)-R8, or -N(R9)-C(R5)=NR6; R5 is hydrogen; alkyl; or alkyl substituted by halogen, alkoxy, haloalkoxy or -S(0)mRi5; Rg and R7 each independently represent hydrogen, alkyl, C3-C5 alkenyl or C3-C5 alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mRi5; or alkyl substituted by phenyl or pyridyl each of which is optionally substituted with one or more groups selected from halogen, nitro and alkyl; or Rfc 7-.i Ry may form together with the nitrogen to which they m^ attached a 3 to 7 membered ring which may additionally contain one or more, heteroatoms selected from oxygen, nitrogen or sulfur; WO 00/35884 PCT/EP99/10452 Rg is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, R]4CO-or-S(0)tR]o; R9 RjO and R]4 are alkyl or haloalkyl; Rj j and R12 are independently selected from halogen, hydrogen, CN and N02; R]3 is selected from halogen, haloalkyl, haloalkoxy, -S(0)qCF?, and -SF5; Rl5 is alkyl or haloalkyl; X is selected from nitrogen and C-Rio; Z is O, S(0)a; or NR7; a, m, n and q are independently selected from 0, 1, and 2; and t is 0 or 2; and veterinarily acceptable salts thereof. In another aspect, the present invention provides a method of controlling parasites in or on an animal comprising administering orally to the animal a parasiticidally effective, substantially non-emetic amount of a 1-arylpyrazole of formula (XX): (XX) wherein: R2oi is cyano, C(0)alkyl, C(S)NH2, alkyl, C(=NOH)NH2 or G(=NNH2)NH2; WO 00/35884 PCT/EP99/10452 R202 is S(O)nR203, C2-C3 alkenyl, C2-C3 haloalkenyl, cycloalkyl. halocycloalkyl or C2-C3 alkynyl; R203 is alkyl or haloalkyl; R204 is -N(R205)C(O)CR206R207R208> -N(R205)C(O)aryl, or -N(R205)C(O)OR207; R205 is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, cycloalkylaJkyl, halocycloalkylalkyl, alkoxyalkyl, haloalkoxyalkyl, C3-C5 alkenyl, CrC5 haloalkenyl, C3-C5 alkynyl, C3-Cj haloalkynyl; R206 is hydrogen, halogen, alkoxy, haloalkoxy, alkoxyalkyl. haloalkoxyalkyl, formyloxy, alkylcarbonyloxy, haloalkylcarbonyloxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl. alkylsulfonyl, haloalkylsulfonyl, alkylamino, dialkylamino, haloalkylamino, di(haloalkyl)amino, cycloalkyloxy, halocycloalkyloxy, alkoxyalkoxy, haloalkoxyalkoxy, alkoxyalkoxyalkoxy, aryloxy, or arylaJkoxy; R207 and R2osare independently hydrogen, alkyl, haloalkyl, cycloalkyl, or halocycloalkyl; or R207 anc^ R208mav ^orm together with the carbon to which they are attached a 3 to 7 membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur; Xj is selected from nitrogen and C-R2i2; R2] 1 and R2\2 are independently selected from halogen, hydrogen, CN and NO ; R213 is selected from halogen, haloalkyl, haloalkoxy, -SCO^CF , and -SF ; and 5' h and k are independently selected frcm 0, 1, and 2; and veterinarily acceptable salts thereof. ^ By the term "veterinarily acceptable salts" is meant salts the anions of which are known and accepted in the art for the formation of salts for veterinary use. Suitable acid addition salts, e.g. formed by WO 00/35884 PCT/EP99/10452 compounds of formulae (I) and (XX) containing a basic nitrogen atom, e.g. an amino group, include salts with inorganic acids, for example hydrochlorides, sulphates, phosphates and nitrates and salts with organic acids for example acetic acid. Unless otherwise specified, alkyl and alkoxy groups are generally lower alkyl and alkoxy groups, that is having from one to six carbon atoms, preferably from one to four carbon atoms. Generally, the haloalkyl, haloalkoxy and alkylamino groups have from one to four carbon atoms. The haloalkyl and haloalkoxy groups can bear one or more halogen atoms; preferred groups of this type include -CF3 and -OCF3. Cycloalkyl groups generally have from 3 to 6 carbon atoms, preferably from 3 to 5 carbon atoms and may be substituted by one or more halogen atoms.. Alkenyl, haloalkenyl, alkynyl, and haloalkynyl groups generally contain from 3 to 5 carbon atoms. By the term aryl is generally meant phenyl, pyridyl, fiiryl, and thiopheneyl, each of which is optionally substituted by one or more halogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, hydroxy, amino, alkylamino or dialkylamino, In compounds of formula (I), by the term substituted alkyl is meant alkyl which is substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mRi5; or alkyl substituted by phenyl or pyridyl each of which is optionally substituted with one or more groups selected from halogen, nitro and alkyl; wherein R15 is alkyl or haloalkyl and m is zero, one or two. Preferably in compounds of formula (I), alkyl groups are generally substituted by from one to five halogen atoms, preferably from one to three halogen atoms. Chlorine and fluorine atoms are preferred. Compounds of formula (I) wherein R4 is -N=C(R5)-Z-R.6, Z is NR7 and R5 represents a hydrogen atom may exist as the tautomeric WO 00/35884 PCT/EP99/10452 double bond isomer form -NH-C(R5)=N-R.7. It is to be understood that both such forms are embraced by the present invention. In compounds of formula (XX) the following examples of radicals are provided: An example of cycloalkylalkyl is cyclopropylmethyl; an example of cycloalkoxy is cyclopropyloxy; an example of alkoxyalkyl is CH3OCH2-; an example of aikoxyalkoxy is CH3OCH20-; An example of alkoxyalkoxyalkoxy is CH3OCH2OCH20-; An example of aryloxy is the phenoxy radical; and An example of the arylalkoxy radical is benzyloxy or 2-phenylethoxy. Generally, in dialkylamino or di(haloalkyl)amino radicals, the alkyl and haloalkyl groups on nitrogen may be chosen independently of one another. It is also to be understood that enantiomeric and diastereomeric forms of the compounds of formulae (I) and (XX) and salts thereof are embraced by the present invention. Compounds of formula (I) may be generally prepared according to known processes, for example as described in European Patent Application 511845 or other processes according to the knowledge of a man skilled in the art of chemical synthesis. By the term non-emetic is meant a compound that does not generally elicit emesis from the animal when a protective, preventative or cleaning dose is administered to the animal. By the term emesis is meant vomiting. Generally an emetic substance elicits the said emesis in less than 24 hours administration, preferably less than S hours, more preferably less than 2 hours. Generally when the compounds of the invention are administered to a population of animals, more than WO 00/35884 PCT/EP99/10452 70% of the animals are free of emesis, preferably more than 80%, most preferably more than 90%. A preferred class of compounds of formula (I) for use in the control of parasites in animals are those wherein; R] is cyano or alkyl; R2 is S(0)nR3; R3 is alkyl or haloalkyl; R4 is -N=C(R5)-Z-R6; R5 is hydrogen, alkyl or haloalkyl; ZisO, S(0)a;orNR7; R6 and R7 are independently selected from hydrogen and unsubstituted or substituted alkyl; or R^ and R7 may form together with the nitrogen to which they are attached a 3 to 7 membered ring which may additionally contain one or more heteroatoms selected from oxygen, nitrogen or sulfur;X is selected from nitrogen and C-R12; Rj 1 and Rj2 are independently selected from halogen, hydrogen, CN and NO ; Rj3 is selected from halogen, haloalkyl, haloalkoxy, -S(0)qCF3, and -SF5; a, n and q are independently selected from 0, 1, and 2. Preferably Rg is alkyl which is substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, sulfide, sulfoxide, ^vifone, or phenyl or pyridyl moieties of which each phenyl or pyridyl moiety is optionally substituted with one or more groups selected from halo, nitro, and alkyl. Preferably the method of the invention has one or more of the following features: WO 00/35884 PCT/EP99/10452 R1 is cyano; R4 is -N=C(R5)-Z-R6 and Z is -NR7; X is C-R12; R] 1 and R12represent a chlorine atom; and R13 is CF3, OCF3or-SF5; R12is-S(0)nCF3 and n is 0,1, or 2. A further preferred class of compounds of formula (I) for use in the control of parasites in animals are those wherein: Rl is cyano or alkyl; R4 is -N=C(R5>Z-R6; and R5 is hydrogen or C1-C3 alkyl. The compounds of formula (I) for use in the control of parasites in animals, preferably have one or more of the following features: R] is cyano or methyl; R3 is halomethyl (preferably CF3); Rl 1 and R12 each independently represent a halogen atom; X is C-R12; R13 is haloalkyl (preferably CF3), haloalkoxy (preferably OCF3), or -SF5; or n is 0, 1 or 2 (preferably 0 or 1). A further preferred class of compounds of formula (I) for use in the control of parasites in animals are those wherein: R1 is cyano; R2isS(0)nR3; R3 is halomethyl; R4 is -N=C(R5)-Z-R(s; Z is NR7; R5 is hydrogen or alkyl; WO 00/35884 PCI7EP99/10452 R6 and R7 each independently represent hydrogen, alky!, alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR15; or alkyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl; X is selected from nitrogen and C-R12 R11 and R12 each independently represent a halogen atom; R13 is selected from haloalkyl, haloalkoxy and -SF5; R15 is alkyl or haloaikyl; and m and n are independently selected from 0, 1, and 2. A further preferred class of compounds of formula (I) for use in the control of parasites in animals is that wherein: R1 is cyano; R2isS(0)nCF3; R4 is -N=C(R5)-Z-R6 or -N=C(R5)-N(R7)-R8; Z is NR7; R5 is hydrogen or alkyl; R5 and R7 each independently represent hydrogen, alkyl, alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR15; or methyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl; R.g is alkcxy, haloalkoxy. aminon alkylamino. dialkylamino cr -S(O)tR10; ' X is selected from nitrogen and C-R12; R10 and R15 independently represent alkyl or haloalkyl; WO 00/35884 PCT/EP99/10452 R11 and R12 each represent a chlorine-atom; R13 is CF3 or -SF5; and m and n are 0, 1 or 2; and t is 0 or 2. A further preferred class of compounds of formula (I) for use in the control of parasites in animals are those wherein: R] is cyano; R2 is S(0)nCF3; R4 is -N=C(R5)-Z-R6; Z is NR7; R5 is hydrogen or methyl; R6 and R7 each independently represent hydrogen, alkyl, alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR15; or alkyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl; Xis C-R12; R11 and R12 each represent a chlorine atom: Rj3isCF3or-SF5; Rj5 is alkyl or haloalkyl; m is zero, one or two; and n is 0 or 1. A further preferred class of compounds of formula (I) for use in the control of parasites in animals are those wherein: Rj is cyano; R2 is S(0)nCF3; R4 is -N=C(R5)-Z-R6; ZisNRy; WO 00/35884 PCT/EP99/10452 R5 and R7 each represent a hydrogen atom; R6 is alkyl or haloalkyl; Xis C-R12; R11 and R12 each represent a chlorine atom; R13 is CF3 or -SF5; and n is 0. Compounds of formula (XX) which are preferred according 10 the present invention are those wherein: wherein: R201 is cyano; R202 is S(O)hR203; R203 is alkyl or haloalkyl; R204 is - N(R205)C(O)CR206R207R208; R205 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl and halocycloalkylalkyl; R2O6 is alkoxy, haloalkoxy, or hydrogen; R207 and R2O8 are independently hydrogen, alkyl, or haloalkyl; or R207 and R2O8 may form together with the carbon to which they are attached a 3 to 7 membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur; Xj is selected from nitrogen and C-R212; R21 j and R212 are independently selected from halogen, hydrogen, CN and NO ; and -SF ; and 5 ' h and k are independently selected from 0,1, and 2. WO 00/35884 PCT/EP99/10452 A preferred group of compounds of formula (XX) is that wherein the ring which is formed by R207 and i R-208 is interrupted by one or more heteroatoms, more preferably one oxygen atom. The compounds of formula (I) of the present invention preferably have one or more of the following features: R-201ls cyano; R203 is halomethyl, preferably CF3; R21 ] and R2J2are independently halogen; X] isC-R2i2; R213 is haloalkyl, haloalkoxy or -SF5; or h is 0 or 1, or 2, preferably 0 or 1. A preferred class of compounds that wherein R204 is N(R205)C(O)CR206R207R208- Another preferred class of compounds that wherein R204 is N(R205)C(O)aryl. Another preferred class of compounds that wherein R204 1S N(R205)C(O)OR207- Preferably R205 is C -C alkyl, more preferably C,-C2 alkyl, most preferably methyl. Preferably R2O6 's alkoxy, most preferably methoxy, ethoxy or propoxy. Preferably R207 ^d R-208 are b°m hydrogen. Among the compounds which may be used in the invention some are new and hence in another aspect of the present invention there is provided a compoundof formula (II): WO 00/35884 PCT/EP99/10452 wherein: R21 is cyano, alkyl, haloalkyl,, acetyl or -C(=S)NH2, C(=NOH)NH2 or C(-NNH2)NH2; R22isS(0)mR23; R23 is alkyl or haloalkyl; R24 is -N=C(R25)N(R26)(R27) or -N=C(R25)-N(R27)-R2g; R25 represents hydrogen or alkyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy or -S(O)mR35; R26 and R27 each independently represent hydrogen, alkyl, alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR35; or alkyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl; wherein R35 is alkyl or haloalkyl and m is zero, one or two; X is selected from nitrogen and C-R32; R28 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino or -S(O),R30; R3O is alkyl or haloalkyl; R3 1 and R32 are independently selected from halogen, hydrogen, CN and N02; WO 00/35884 PCT/EP99/10452 R33 is selected from halogen, haloalkyl, haloalkoxy, -S(0)rCF., and-SF5; m and r are independently selected from 0, 1, and 2; and t is 0 or 2; with the exclusion of the compound wherein R2] is cyano; R22 is - SCF2CH3; R25 is hydrogen; X is C-R32; R26 ^d ^27 are rnethyl; R3 ] and R32 are chlorine; and R33 is trifluoromethyl; and veterinarily acceptable salts thereof. A further class of novel compounds of formula (II) are those wherein: R21 is cyano or methyl; R22isS(0)mR23; R23 is haloalkyl; R24is-N=C(R25)N(R26)(R27); R25 and R27 are hydrogen or unsubstituted or substituted alkyl; R26 is haloalkyl; X is selected from nitrogen and C-R32; R3 ] and R32 are independently selected from halogen, hydrogen, CN and NO2; R33 is selected from halogen, haloalkyl, haloalkoxy, -S(0)rCF , and -SF5; m and r are independently selected from 0, 1, and 2; with the exclusion of the compound wherein R2] is cyano; R22 is -SCF2CH3; R25 is hydrogen; X is C-R32; R26 a"0" R27 *£ methyl; R3 \ and R32 are chlorine; and R33 is trifluoromethyl. A preferred class of novel compounds of formula (II) are those wherein: R21 is cyano; R22 is S(0)mR23; WO 00/35884 PCT/EP99/10452 R23 is halomethyl; R24is-N=C(R25)N(R26)(R27); R25 is hydrogen or alkyl; R26 and R27 each independently represent hydrogen, alkyl, alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR]5; or alkyl substituted by phenyl or pyridyl each of which is optionally substituted with one or more groups selected from halogen, nitro and alkyl: wherein R15 is alkyl or haloalkyl and m is zero, one or two; X is selected from nitrogen and C-R32; R3 j and R32 each represent a chlorine atom; R33 is selected from haloalkyl, haloalkoxy and -SF5; m is selected from 0,1, and 2. A further preferred class of novel compounds of formula (II) are those wherein: R21 is cyano; R22 is S(0)mCF3; R24 is -N=C(R25)N(R26)(R27); or -N=C(R25)-N(R27)-R28; R25 is hydrogen or methyl; R26 and R27 each independently represent hydrogen, alkyl, alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR]5; or methyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl; wherein R] 5 is alkyl or haloalkyl and m is zero, one or tv"v R28 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino or -S(p)tR30; X is selected from nitrogen and C-R32; WO 00/35884 PCT/EP99/104S2 R30 is alkyl or haloalkyl; R=and R39 each represent a chlorine atom; R33 is CF3 or -SF5; and m is 0, 1 or 2; and t is 0 or 2. A more preferred class of novel compounds of formula (II) are those wherein: R21 is cyano; R22 is(0)mCF3; R24 is -N=C(R25)N(R26)(R27); R25 and R27 each independently represent hydrogen or methyl; R-26 represents hydrogen, alkyl, alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mRi5; or methyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl; wherein R15 is alkyl or haloalkyl and m is zero, one or two; X is selected from nitrogen and C-R32; R3 ] and R32 each represent a chlorine atom; R33 is CF3 or -SF5; and m is 0, 1 or 2. An especially preferred class of novel compounds of formula (II) are those wherein: R2] is cyano; R22 is S(0)mCF3; R24 iS"' -~M;R25' (R-26A'"'27.>' R25 and R27 each represent a hydrogen atom; " R26 is alkyl or (preferably) haloalkyl; X is C-R32; WO 00/35884 PCJ7EP99/I0452 R31 and R32 each represent a chlorine atom; R33 is CF3 or -SF5; and m is 0. In another aspect of the present invention there is provided an compound of formula (XX) or a salt thereof as hereinbefore defined, provided that the compound is not 3-cyano-l -(2,6-dichloro-4-trifluoromethylphenyl)-5-(N-ethoxycarbonyl-N-methyl)amino-4-trifluoromethylthiopyrazole. Most preferably, the following compounds of formula (I) and (XX) are preferred according to the present invention as listed in Tables 1 to 13. The Compound Numbers are for identification purposes only. The following symbols are hereby defined: Me means methyl; Et means ethyl; n-Pr means n-propyl; i-Pr means isopropyl; n-Bu means n-Butyl, and n-Pent means n-Pentyl; Cy means cyclopropyl. Table 1 Compounds of formula (I) wherein R1 is cyano; R2 is SCF3; R11 is CI, X is C-Cl, R4 is -N=C(R5)ZR6, Z is NR7, R7 is H, and Rj3 is CF3 or SF5. WO 00/35884 PCT/EP99/10452 Table 2 Compounds of formula (1) wherein Rj is cyano; K\ \ is CI; R4 is -N=C(R5)ZR6and Z is NR7 WO 00/35884 PCT/EP99/10452 Note: Compound number 232 is the acetate salt, and compound number 233 is the citrate salt. Table 3 Compounds of formula (I) wherein R] is cyano; R11 is CI; and R4 is -N=C(R5)-N(R7)-Rg. The following compounds of formula (XX) are preferred according to the present invention as listed in Tables 4-12. Table 4 WO 00/358 PCT/EP99/10452 WO 00/35884 PCT/EP99/104S2 -21 - •7^ WO 00/35884 PCT/EP99/10452 WO 00/35884 PCT/EP99/10452 WO 00/35884 PCT/EP99/10452 WO 00/35884 PCT/EP99/1045: WO 00/35884 , PCJ7EP99/I0452 Compound 1-11 was also separated into its diastereomers, (R)l-l 1 and (S)l-11 . Table 10 Compounds of formula (XX) wherein R201 is cyano; R204 is 5 N(R205)C(O)CR206R207R208; R207 and R208 are H; R2] ] is CI, X] is C-Cl: and R213 is CF3 or SF5. 10 ' Table 11 Compounds of formula (XX) wherein R201 is cyano; R204 is WO 00/35884 PCT/EP99/1045: WO 00/35884 PCT/EP99/10452 Table 12 Compounds of formula (XX) wherein R201 is cyano; R202 is S(O)hCF3;R204isN(R205)C(O)CR206R207R208;R211'sCl;X1 is 5 C-Cl, andR213isCF3orSF5. WO 00/35884 -29- Table 13 Compounds of formula (XX) wherein R2oi is cyano; R202 '■' S(0)hCF3; R204 is N(R205)C(O)aryl: R2i 1 is Cl; X] is C-Cl, R205 is CH3; and R2i3 is CF3 or SF5. Within this table the following symbols are defined: Ph means phenyl; Fu means furyl Th means the thiophene radical Pyr means pyridyl WO 00/35884 PCT/EP99/1045: WO 00/35884 PCT/EP99/10452 The present invention also relates to a composition comprising a parasiticidally effective, substantially non-emetic amount of a compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof and an acceptable carrier. Acceptable carriers for the use of the compounds are generally known to the skilled addressee concerned with pest control in animals, particularly domestic animals, most preferably dogs or cats. The compositions which can be used in the invention can comprise generally from about 0.001 to 95% of the compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof. The remainder of the composition up to 100% comprises a carrier as well as generally various additives. In this specification and the accompanying claims, percentages are by weight. The diluted liquid formulations generally comprise from about 0.001 to about 3% of compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof, preferably from about 0.1 to about 0.5%. Solid formulations generally comprise from about 0.1 to about 8% of compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof .preferably from about 0.5 to about 1.5%. Compositions for oral administration comprise one or more of the compounds of general formula (I) or salts thereof or compounds of formula (XX) or salts thereof in association with veterinarily acceptable carriers or coatings and include, for example, tablets, pills, capsules, gels, drenches, medicated feeds, medicated drinking water, medicated dietary supplements, slow-release boluses or other slow-release devices intended to be retained within the gastro-intestinal tract. Any of ihcs? may incorporate the active ingredients contained within micro-capsules or coated with acid-labile or alkali-labile or other pharmaceutically acceptable enteric coatings. Feed premixes or concentrates containing WO 00/35884 PCT/EP99/104 compounds of the present invention for use in preparation of medicated diets, drinking water or other materials for consumption by animals may also be used. In a highly preferred embodiment, the compositions are administered postprandially, preferably from just after a meal to 2 hours after the meal. In a highly preferred embodiment, there is provided a product which is readily chewed by the animal and which product does generally not allow human contamination when the product is provided to the animal by hand. The compounds of general formula (I) or salts thereof or compounds of formula (XX) or salts thereof may be administered before, during or after meals The compounds of general formula (I) or salts thereof or compounds of formula (XX) or salts thereof may be mixed with a carrier and/or a foodstuff. According to the present invention the compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof is administered orally in a dose to the animal in a dose range generally from 0.1 to 500 mg/kg of the compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof per kilogram of animal body weight (mg/kg), preferably from 1 to 100 mg/kg, more preferably from 1 to 50 mg/kg, even more preferably from 2 to 25 mg/kg, most preferably from 3 to 15 mg/kg According to the present invention, the frequency of treatment of the animal, preferably the domestic animal to be treated by the compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof is generally from about once per week to about nnce per year, preferably from about once every two weeks to about once every six months, more preferably from about once every two weeks to once every three months, and most preferably from about once every two weeks to about once every six weeks. WO 00/35884 PCT/EP99/J 0452 Generally the animal to be treated is adomestic animal, preferably a domesiic companion animal. More preferably the animal to be treated is a dog and/or a cat. The compounds of the invention may be administered most advantageously with another parasiticidally effective material, such as an endoparasiticide, and/or an ectoparasiticide, and/or an endectoparasiticide. For example, such compounds include macrocyclic lactones such as avermectins or milbemycins e.g., ivermectin; pyratei (generally adminsitered as pyrantel pamoate) or an insect growth regulator such as lufenuron or methoprene. By the term "parasites" as used in the specification and claims is meant endoparasites and ectoparasites of warm-blooded animals, particularly ectoparasites. Preferably, fleas and/or ticks are controlled by the method of the present invention. Illustrative of specific parasites of various host animals which may be controlled by the method of this invention include arthropods such as: Mites: Mesostigmata spp. e.g. mesostigmatids such as the chicken mite, Dermanvssus gallinae; itch or scab mites such as Sarcoptidae spp. for example Sarcoptes scabiei; mange mites such as Psoroptidae spp. including Chorioptes bovis and Psoroptes ovis; chiggers e.g. TrombicuJidae spp. for example the north american chigger, Trombicula alfreddugesi: Ticks: e.g., soft-bodied ticks including Argasidae spp. for example Arpas spp. and Ornithodoros spp ; hard-bodied ticks including Ixodidae spp., for example Rhipicephalus sanguineus, and Boophilus spp.; lice, e.g., Haematopinus spp., Linognathus spp. and Solenopotes spp.; „ Fleas: e.g., Ctenocephalides spp., such as dog flea (Ctenocephalides canis) and cat flea (Ctenocephalides felis); Xenopsvlla WO 00/35884 PCT/EP99/J0452 spp. such as oriental rat flea [Xenopsvlla cheopisl: and Pulex spp. such as human flea [Pulex irritans]; True bugs: e.g., Cimicidae or including the common bed bug (Cimex lectularius);, Triatominae spp. including triatomid bugs also known as kissing bugs; for example Rhodnius prolixus and Triatoma spp.; bloodsucking adult flies: (e.g., horn fly fHaematobia irritans], horse fly [Tabanus spp.], stable fly [Stomoxvs calcitransl. black fly [Simulium spp.], deer fly [Chrvsops spp.], louse fly [Melophagus ovinusl, tsetse fly [Glossina spp.], mosquitoes [Culex spp., Anopheles spp.. and Aedes spp.); and parasitic fly maggots: (e.g., bot fly [Oestrus ovis and Cuterebra spp.], blow fly [Phaenicia spp.], screwworm fCochliomvia hominivorax], cattle grub [Hypoderma spp.], fleeceworm. The present invention also relates to a use of a compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof hereinbefore described as a therapeutic agent, preferably for animals, more preferably for domestic animals. The veterinary composition may be sterile or non-sterile. It may be a liquid (e.g. aqueous) or solid (e.g., dry) composition, in particular a freeze-dried composition, which, by addition of water or another liquid, orally effective solutions may be prepared. The present invention also relates to a use of a compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof as hereinbefore defined for the manufacture of a veterinary composition for the control of parasites in or on an anirr.2! The present invention also relates to a method of cleaning animals in good health comprising the application to the animal of a WO 00/35884 PCT/EP99/10452 compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof as hereinbefore defined to the animal. The method of cleaning an animal is not a method of treatment by therapy of the animal body per se, because (a) the animal is in good health and requires no substantial treatment to correct a deficiency of health; (b) the cleaning of the animal is not intended to be done by veterinary personnel, but by persons interested in the cleaning of the animal: and (c) the purpose of such cleaning is to avoid unpleasant conditions for humans and the environment in which humans inhabit so as to not infest the said humans with arthropods carried by the animal. By "carrier" is meant an organic or inorganic material, which can be natural or synthetic, and which is associated with the compound and which facilitates its application to the animal. This carrier is thus generally inert and should be arthropocidally acceptable. The carrier can be solid (e.g., clay, silicates, silica, resins, wax.) or liquid (e.g., water, alcohols, ketones, oil solvents, polar aprotic solvents) An example of an oil solvent is corn oil. An example of a polar aprotic solvent is dimethyl sulfoxide. INCORPORERThe compounds of formula (II) wherein R21, R22, R24, R31, R33 and X are as defined above may be prepared from the compounds of formula (III): WO 00/35884 PCT/EP99/I0452 (III) wherein R21, R22' R31- R33 and X are as defined above, using processes described in European Patent Publications 0511845 or 0659745. According to a feature of the present invention, compounds of formula (II) wherein R21. R22 R 31 R 33 and X are as defined above and R24 is -N=C(R25)-NR26R27 wherein R25 R26 and R27 are as defined above may be prepared by reacting a compound of formula (111) with a compound of formula (IV): wherein R25, R26 and R27 are as defined above and R100 is generally an alkyl group. The reaction is optionally conducted in the presence of a catalyst such as a mineral or organic acid (for example hydrochloric acid), generally using from 1 to 100 equivalents of (IV), preferably using 1 to 10 equivalents of (IV), and is preferably conducted in an organic solvent such as tetrahydrofuran, toluene, or N,N-dimethylformamide, at a temperature of from 0°C to 150°C. Additional adjuvants such as drying agents (e.g. magnesium sulfate, potassium carbonate, or molecular sieves) may also be advantageous to the reaction. Compounds of formula (IV) are known or may be prepared by known procedures. According to a feature of the present invetion compound of formula (II) wherein R21, R22 R1 R-33 and X are as defined above and 24 is -N=C(R25)-NR26R.27 wherein R25, R26 and R27 are as WO 00/35884 PCT/EP99/10452 defined above, may be prepared by the reaction of a compound of formula (V): (V) wherein R21, R22- R25' R-31-R33'X and R100 are as defined above, with a compound of formula (VI): R27^ H (VI) wherein R26 and R27 are as defined above. The reaction is generally conducted using the same conditions as used for the preparation of compounds of formula (II) by the reaction of compounds of formula (III) with compounds of formula (IV). According to a feature of the present invention, compounds of formula (II) wherein R24 is -N=C(R25)-NR27R28> ^d R2], R22' R-25> R27, R31, R33 and X are as defined above, and R28 is COR34 wherein R34 is as defined above, may be prepared by the reaction of the corresponding compounds of formula (II) wherein R24 is -N=C(R25)-xiR-nH with an acid chloride of formula (VIP: R34COCI (VII) •- wherein R34 is as defined above. The reaction is generally performed in the presence of a base such as a trialkvlamine for example WO 00/35884 PCT/EP99/10452 triethylamine in a solvent such as dichlororriethane, at a temperature of from 0°C to 50°C According to a feature of the present invention, compounds of formula (II) wherein R24 is -N=C(R25)-NR27R28, an(^ R21- R22>R25-R27. R31, R33 and X are as defined above and Rog is -S(O)tR30 may be prepared by the reaction of the corresponding compound of formula (11) wherein R24 is -N=C(R25)-NR27H with a sulfonyl chloride or a sulfenyl chloride of formula (VIII): R30S(O)tCl (VIII) The reaction is generally performed in the presence of a weak base such as a trialkylamine for example triethylamine, or pyridine in a solvent such as dichloromethane, at a temperature of from 0°C to 50°C. Compounds of formula (VI), (VII) and (VIII) are known or may be prepared by known procedures. Compounds of formula (III) and (V) may be generally prepared according to known processes, for example as described in International Patent Publications WO 87/3781, WO 93/6089, WO 94/21606 WO 97/07102, WO 98/24767,, WO 98/28277, WO 98/28278 and WO 98/28279,, European Patent Application 295117, 846686, and United States Patent 5232940.. In another aspect of the present invention, compounds of formula (XX) wherein R204 is -N(R205)C(O)CR206R207R208> N(RvuvC(G)aryi, or N(R205)C(G')OR207 ^ generally prepared from compounds of formula (XXI): WO 00/35884 PCT/EP99/J0452 respectively by reaction with halides of formulae X2C(O)CR206R207R208> X2C(0)aryl, or X2C(O)OR207, wherein R201> R202> R205> R206' R207> R208> R21 ]. R213> and xl are defined above and wherein X2 is a halogen atom. The reaction is generally carried ouT in the presence of a base, generally using from 1 to 10 molar equivalents of the halide, and is preferably conducted in the presence of an organic solvent such as tetrahydrofuran, methylene chloride, at a temperature of from 0°C to 150°C. Compounds of formula (XXI) may be prepared from a compound of formula (XXII): WO 00/35884 PCT/EP99/10452 . (XXII) : by reaction with a compound of formula (XXIII): X2R205(XXIII) wherein R201, R202. R205, R211, R213, XI and X2 are defined above. Compounds of formula (XXIII) are generally known in the art as alkylhalides or substituted alkylhalides. Compounds of formula XX11 may be prepared by methods described in International Patent Publications WO 87/3781, WO 93/6089, WO 94/21606, WO 97/07102, WO 98/24767,, WO 98/28277, WO 98/28278 and WO 98/28279, European Patent Application 295117, 659745, 846686, and United States Patent 5232940 or other methods known to the person skilled in the art. Alternatively compounds of formula (XXI) may be prepared by reduction of compounds of formula (XXIV): (XXIV) wherein k 201R 202,R211 R213 and X1 are defined above. The reduction generally is effected by the use of a standard hydride ion donor, for example sodium borohydride or sodium cyanoborohydride. The reaction is generally effected in an polar solvent such as ethanol or WO 00/35884 PCT7EP99/10452 methanol and generally using from 1 to 10 molar equivalents of the hydride, and is preferably conducted at temperature of from -100°C to 150°C. Compounds of formula (XXIV) may be prepared using methods described in EP 295117, WO 97/22593 or other methods known to those skilled in the art. In another aspect of the invention there are provided the compounds 3-Cyano-1 -(2,6-dichloro-4-trifluoromethylphenyl)-5-ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole and 3-cyano-1 -(2,6-dichloro-4-trifluoromethylphenyl)-5-rnefhylarnino-4-trifluoromethylsulfinylpyrazole which are useful intermediates for the preparation of compounds for use according to the present invention. Biological Example Compounds 1-1, 2-1, 3-1,4-1, 11-1, 13-1, 28-1, 31-1, 32-1, 36-1, 37-1,38-1, 1-3,2-3,3-3.4-3,6-3,41-3, 1-5,2-5,3-5,6-5, 11-5,27-5, 28-5, 1-7,3-7,5-7, 1-9, 1-11,6-11,7-11, 1-12, 11-12,13-12,67-1,68-1, 69-1, 70-1, 72-1, 75-1, 76-1, 77-1, 78-1, 79-1, 80-1, 81-1, 82-1, 115-1, 116-1, 117-1,118-1, 119-1, 120-1, 121-1, 122-1,123-1,124-1,211-1, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, R3-3, S3-3, Rl-7, Sl-7, (R,S)l-9, (R,R)l-9, (S,R)l-9, (S,S) 1-9, S1-11.R1-11, 126-1, 127-1 and 130-1 were formulated as a 30 mg/mL formulations in a 1:1 volume/volume solution of dimethyl sulfoxide and corn oil Using this formulation, mixed breed dogs and cats were treated at a rate of 10 me of the compond per kg(mg/kg)of hoHv weight of the dog and 20 mg/kg of the cat treated. The animals were fasted for at least 8 hours prior to treatment, fed half of the daily ration WO 00/35884 PCT/EP99/10452 immediately prior to treatment, then allowed access to the remainder of the daily ration immediately following treatment. All dogs were infested with cat fleas (Ctenocephalides felis) and with ticks (Rhipicephalus sanguineus) 1 day prior to administration of the compound. Cats were only infested with fleas. The initial flea and tick counts were performed 1 day after the administration of the compounds. At 7, 14, 21 and 28 days after treatment the dogs were re-infested with ticks and 8, 15, 22 and 29 days after treatment the dogs and cats were re-infested with fleas. At 1, 9, ) 6, 23 and 30 days after treatment the control of fleas and ticks in treated dogs and cats was determined versus a group of infested dogs and cats which received a placebo consisting of a 1:1 volume/volume solution of dimethyl sulfoxide and corn oil. To determine the efficacies of the compounds, the arthropods were combed from the animals and counted. In the animals treated with the compounds above, there was substantially no emesis after 2, 8 and 24 hours. Generally long-term control of fleas and ticks was provided in dogs. In the cats treated, there was commercially acceptable control of fleas for at least one day post treatment. The results of this example were superior to those obtained with compounds of the prior art, for example, fipronil. The following non-limiting Synthesis Examples illustrate the preparation of compounds of formula (I) and the Reference Examples illustrate the preparation of intermediates used in their synthesis. Synthesis Example 1 A solution of 5-amino-3-cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylthiopyrazole (1 g) inN.N- dimefhylformamide dimethyl acetal was heated at 50PC for 1 hour. i WO 00/35884 PCT/EP99/10452 Evaporation of solvents gave 3-cyano-} -(2,6-dichloro-A-trifluoromeihylphenyO-S-N'-dimethylaminomethylideneamino^-uifluoromethylthiopyrazole m.p.l41°C. By proceeding in a similar manner the following compounds were also prepared: 3-cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5-N'-dimethylarrunomethylideneamino-4-trifluoromethylsulfonylpyrazole m.p.209°C; and 3-cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5-N'-dimethylaminomethylideneamino-4-trifluoromethylsulfinylpyrazole m.p.207°C. Synthesis Example 2 A solution of 3-cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5-ethoxymethylideneamino-4-trifluoromethylthiopyrazole (5 g) in ethanol was treated with benzylamine (11.4 ml), stirred overnight, evaporated and purified by reverse-phase column chromatography (C-18 stationary phase column, eluting with MeOH/water) to give 5-N'-benzylaminomethylidenearnino-3-cyano-1 -(2,6-dichloro-4-trifluoromethylphenyl)- 4-trifluoromethylthiopyrazole 1.18 g), m.p.l 13°C. By proceeding in a similar manner the compounds of formula (II) wherein R2j is CN; R24 is -N=CH-NHR26; ^31 is CI; X is C-Cl; and R33 is CF3 shown in Table 4 were also prepared. Table 4 Compd No. R22 R26 M.P.°C ?l SCR CH2CN 175 211-1 SCF3 CH2CF3 130 222 SCF3 CH3 173 223 SOCF3 CH2Ph 173 225 SOCF3 CH3 144 226 SOCF3 CH3 144 WO 00/35884 PCT/E P99/10452 1227 SOCF3 CH2CF3 175 228 S02CF3 2-propynyl 149 229 S02CF3 CH2Ph 182 230 S02CF3 CH2CF3 183 209-1 SCF3 iPr 207-1 SCF3 CH2CH3 141 Reference Example 1 A solution of 5-amino-3-cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylthiopyrazole (500 g) in methyl orthoformate was treated with concentrated hydrochloric acid (10 ml) and heated at 50oC After 8 hours the reaction mixture was evaporated to give a solid which was washed (heptane) and air-dried to give 3-cyano-1 -(2,6-dichloro-4-trifluorornethylphenyl)-5-ethoxymeihylideneamino-4-trifluorornethylthiopyrazole (217 g), m.p. 68°C. By proceeding in a similar manner the following intermediates were also prepared: 3-cyano-1 -(2.6-dichloro-4-trifluoromethylphenyl)-5-ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole, m.p.63°C; and 3-cyano-1 -(2,6-dichloro-4-trifluoromethylphenyl)-5-ethoxymethyIideneamino-4-trifluoromethyIsulfonylpyrazole, m.p.118oC Synthesis Example 3 3-Cyano-1 -(2,6-dichIoro-4-trifluoromethylphenyl)-5- mctH>i^i)iiiu-4-uintioromethyisuifrnyipyra2oie (111.55 g, 0.247 moles), triethylamine (62.45 g, 0.618 moles), 4-dimethylaminopyridine (3 g, 0.0247 moles), and tetrahydrofuran (700 ml) was combined. The resulting solution was heated to 45°C and ethoxyacetyl chloride (45.2 g, WO 00/35884 PCT/EP99/10452 0.37 mmol) was added dropwise over 10 min. After 1 h. the mixture was evaporated to a brown residue, which was dissolved in 500 ml of ethyl acetate and washed with 2 x 300 ml of water. The organic phase was dried over magnesium sulfate, filtered, and evaporated to a brown oil. The oil was triturated with 1 L of hot cyclohexane. The resulting solids were collected by filtration and washed with 500 ml of hoi cyclohexane, then air dried to afford of compound 3-3 as a beige powder (116.7 g). Evaporation of the mother liquors afforded a second crop of compound 3-3 (8.4 g). In a similar fashion or by modifications according to methods known to the skilled addressee, the following compounds were prepared. The compound numbers in the left column refer to the Tables cited above. Compound Number Mass Spectral molecular ion + 1 (M+l) 1-1 477 2-1 507 3-1 521 4-1 535 11-1 505 13-1 549 28-1 537 31-1 517 32-1 531 36-1 535 37-1 521 38-1 535 1-3 593 2-3 523 WO 00/35884 PCT/EP99/10452 WO 00/35884 PCT/EP99/10452 Reference Example 2: Step A: Preparation of 3-Cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5~ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole. A 12-L inrec-neeked nask. titled with an uverhcau simcr, heating mantle, water separaior (e.g. Dean Stark trap) with condenser was placed under a nitrogen atmosphere and charged with 1.475 kg (3.37 moles) of fipronil and 6 L of triethyl orthoformate. The suspension was WO 00/35884 PCT7EP99/10452 heated to reflux over 2.5 h, then at reflux for 3 h with collection and removal of the distillate. The mixture was cooled to room temperature, then evaporated under reduced pressure at a bath temperature of 60-80°C, then at 50°C overnight. The resulting beige solid, 1.717 kg (95.8 % by HPLC, 3.335 moles, 99% purity corrected yield) was used without further purification, (m.p. about 63°C) Step B: Preparation of 3-Cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5-methylamino-4-trifluoromethylsulfinylpyrazole. A 50 L reactor was charged with 3-Cyano-l-(2,6-dichloro-4-trifluoromethyIphenyl)-5-ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole (1.645 g, 3.335 moles) and absolute ethanol (16 L) under nitrogen. The solution was cooled to 10°C, and sodium borohydride (266 g, 7.03 moles) was added slowly such that the temperature, remained generally below 35°C. After 6.75 h, some additional sodium borohydride (25 g, 0.66 moles) was added and stirring was continued overnight. Acetic acid (1.3 L, 22.7 moles) was added to quench, followed by 16 L of water. The resulting precipitate was collected by filtration, washed with water, and air-dried. Recrystallization from methanol afforded 3-Cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5-rnethylamino-4- trifluoromethylsulfinylpyrazole (350 g) as an off-white solid, (m.p. about 227OC WE CLAIM: 1. A 1 -arylpyrazole of formula (XX): (XX) Wherein: R201 is cyano; R202 is S(O)hR203; R203 is alkyl or haloalkyl; R204 is —N(R205)C(O)CR206 R207 R208; R205 is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, cycloalkylalkyl or halocycloalkylalkyl; R206 is alkoxy, haloalkoxy, alkoxyalkyl or haloalkoxy-alkyl; R207 and R208 are each hydrogen; Xi is nitrogen or C-R212; R211 and R212are, independently, halogen, hydrogen, CN or NO2; R213 is halogen, haloalkyl, haloalkoxy, -S(0)kCF3, or -SF5; and h and k are, independently, 0, 1 or 2; or a veterinarily acceptable salt thereof. 2. A composition comprising a parasiticidally effective substantially non-emetic amount from 0.001 to 95% of a compound as claimed in claim 1, or a veterinarily acceptable salt thereof, and a veterinarily acceptable carrier therefor. Dated this on 25th May, 2001 [Dr. Anushri Gupta] of REMFRY & SAGAR Attorney for the Applicants

Full Text

FORM 2
THE PATENTS ACT 1970
[39 OF 1970]
COMPLETE SPECIFICATION [See Section 10]
"CONTROL OF ARTHROPODS IN ANIMALS"
AVENTIS CROPSCIENCE S.A., a French body corporate of 55 Avenue Rene Cassin, F-69006 Lyon, France,
The following specification particularly describes the nature of the invention and the manner in which it is to be performed :-

Control of Arthropods in Animals
The present invention relates to a method of control of parasites in animals, compositions comprising a compound effective for the said control and new compounds effective against parasites.
It is generally a goal of agronomists and veterinarians to possess sufficient means to control pests, particularly arthropods, when they attempt to invade or attack mammals, particularly domestic animals and/' or livestock. A classical method of controlling such pests has been the use of topical and/or systemic pesticides on or in the domestic animal which is being attacked. Generally effective treatments include the oral administration of insect growth regulators, such as lufenuron, or antihelminth compounds such as an ivermectin or an avermectin, or the topical application of the insecticide fipronil. It is advantageous to apply pesticides to animals in oral form so as to prevent the possible contamination of humans or the surrounding environment.
It is an object of the present invention to provide new pesticides which may be used in domestic animals.
Another object of the invention is to provide safer pesticides for domestic animals.
Another object of the invention is to provide new pesticides for domestic animals that may be used in lower doses than existing pesticides.
These objects are met in whole or in part by the present invention.
The present invention provides a method of controlling parasites in or on an animal comprising admini ferine orally to the animal a parasiticidally effective, substantially non-emetic amount of a 1-arylpyrazole of formula (I):

WO 00/35884 PCT/EP99/10452

wherein:
R\ is cyano, acetyl, C(S)NH2, alkyl, haloalkyl, C(=NOH)NH2 or
C(=NNH2)NH2;
R.2 is S(0)nR3; C2-C3 alkenyl, C2-C3 haloalkenyl, cycloalky],
halocycloalkyl or C2-C3 alkynyl; R3 is alkyl or haloalkyl;
R4 is -N=C(R5)-Z-R^, -N=C(R5)-N(R7)-R8, or -N(R9)-C(R5)=NR6;
R5 is hydrogen; alkyl; or alkyl substituted by halogen, alkoxy, haloalkoxy or -S(0)mRi5;
Rg and R7 each independently represent hydrogen, alkyl, C3-C5
alkenyl or C3-C5 alkynyl; or
alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mRi5; or alkyl
substituted by phenyl or pyridyl each of which is optionally substituted with one or more groups selected from halogen, nitro and alkyl; or
Rfc 7-.i Ry may form together with the nitrogen to which they m^
attached a 3 to 7 membered ring which may additionally contain one or more, heteroatoms selected from oxygen, nitrogen or sulfur;

WO 00/35884

PCT/EP99/10452

Rg is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino,
R]4CO-or-S(0)tR]o;
R9 RjO and R]4 are alkyl or haloalkyl;
Rj j and R12 are independently selected from halogen, hydrogen, CN and N02;
R]3 is selected from halogen, haloalkyl, haloalkoxy, -S(0)qCF?, and -SF5;
Rl5 is alkyl or haloalkyl;
X is selected from nitrogen and C-Rio;
Z is O, S(0)a; or NR7;
a, m, n and q are independently selected from 0, 1, and 2; and t is 0 or 2; and veterinarily acceptable salts thereof. In another aspect, the present invention provides a method of controlling parasites in or on an animal comprising administering orally to the animal a parasiticidally effective, substantially non-emetic amount of a 1-arylpyrazole of formula (XX):

(XX)
wherein:
R2oi is cyano, C(0)alkyl, C(S)NH2, alkyl, C(=NOH)NH2 or G(=NNH2)NH2;

WO 00/35884 PCT/EP99/10452

R202 is S(O)nR203, C2-C3 alkenyl, C2-C3 haloalkenyl, cycloalkyl. halocycloalkyl or C2-C3 alkynyl; R203 is alkyl or haloalkyl;
R204 is -N(R205)C(O)CR206R207R208> -N(R205)C(O)aryl, or -N(R205)C(O)OR207;
R205 is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, cycloalkylaJkyl, halocycloalkylalkyl, alkoxyalkyl, haloalkoxyalkyl, C3-C5 alkenyl, CrC5 haloalkenyl, C3-C5 alkynyl, C3-Cj haloalkynyl;
R206 is hydrogen, halogen, alkoxy, haloalkoxy, alkoxyalkyl. haloalkoxyalkyl, formyloxy, alkylcarbonyloxy, haloalkylcarbonyloxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl. alkylsulfonyl, haloalkylsulfonyl, alkylamino, dialkylamino, haloalkylamino, di(haloalkyl)amino, cycloalkyloxy, halocycloalkyloxy, alkoxyalkoxy, haloalkoxyalkoxy, alkoxyalkoxyalkoxy, aryloxy, or arylaJkoxy;
R207 and R2osare independently hydrogen, alkyl, haloalkyl,
cycloalkyl, or halocycloalkyl; or R207 anc^ R208mav ^orm together with the carbon to which they are attached a 3 to 7 membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;
Xj is selected from nitrogen and C-R2i2;
R2] 1 and R2\2 are independently selected from halogen, hydrogen, CN and NO ;
R213 is selected from halogen, haloalkyl, haloalkoxy, -SCO^CF ,
and -SF ; and
5'
h and k are independently selected frcm 0, 1, and 2;
and veterinarily acceptable salts thereof. ^ By the term "veterinarily acceptable salts" is meant salts the anions of which are known and accepted in the art for the formation of salts for veterinary use. Suitable acid addition salts, e.g. formed by

WO 00/35884 PCT/EP99/10452

compounds of formulae (I) and (XX) containing a basic nitrogen atom, e.g. an amino group, include salts with inorganic acids, for example hydrochlorides, sulphates, phosphates and nitrates and salts with organic acids for example acetic acid.
Unless otherwise specified, alkyl and alkoxy groups are generally lower alkyl and alkoxy groups, that is having from one to six carbon atoms, preferably from one to four carbon atoms. Generally, the haloalkyl, haloalkoxy and alkylamino groups have from one to four carbon atoms. The haloalkyl and haloalkoxy groups can bear one or more halogen atoms; preferred groups of this type include -CF3 and -OCF3. Cycloalkyl groups generally have from 3 to 6 carbon atoms, preferably from 3 to 5 carbon atoms and may be substituted by one or more halogen atoms.. Alkenyl, haloalkenyl, alkynyl, and haloalkynyl groups generally contain from 3 to 5 carbon atoms. By the term aryl is generally meant phenyl, pyridyl, fiiryl, and thiopheneyl, each of which is optionally substituted by one or more halogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, hydroxy, amino, alkylamino or dialkylamino, In compounds of formula (I), by the term substituted alkyl is meant alkyl which is substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mRi5; or alkyl substituted
by phenyl or pyridyl each of which is optionally substituted with one or more groups selected from halogen, nitro and alkyl; wherein R15 is
alkyl or haloalkyl and m is zero, one or two. Preferably in compounds of formula (I), alkyl groups are generally substituted by from one to five halogen atoms, preferably from one to three halogen atoms. Chlorine and fluorine atoms are preferred.
Compounds of formula (I) wherein R4 is -N=C(R5)-Z-R.6, Z is NR7 and R5 represents a hydrogen atom may exist as the tautomeric

WO 00/35884 PCT/EP99/10452

double bond isomer form -NH-C(R5)=N-R.7. It is to be understood that both such forms are embraced by the present invention.
In compounds of formula (XX) the following examples of radicals are provided:
An example of cycloalkylalkyl is cyclopropylmethyl;
an example of cycloalkoxy is cyclopropyloxy;
an example of alkoxyalkyl is CH3OCH2-;
an example of aikoxyalkoxy is CH3OCH20-;
An example of alkoxyalkoxyalkoxy is CH3OCH2OCH20-;
An example of aryloxy is the phenoxy radical; and
An example of the arylalkoxy radical is benzyloxy or 2-phenylethoxy.
Generally, in dialkylamino or di(haloalkyl)amino radicals, the alkyl and haloalkyl groups on nitrogen may be chosen independently of one another.
It is also to be understood that enantiomeric and diastereomeric forms of the compounds of formulae (I) and (XX) and salts thereof are embraced by the present invention. Compounds of formula (I) may be generally prepared according to known processes, for example as described in European Patent Application 511845 or other processes according to the knowledge of a man skilled in the art of chemical synthesis.
By the term non-emetic is meant a compound that does not generally elicit emesis from the animal when a protective, preventative or cleaning dose is administered to the animal. By the term emesis is meant vomiting. Generally an emetic substance elicits the said emesis in less than 24 hours administration, preferably less than S hours, more preferably less than 2 hours. Generally when the compounds of the invention are administered to a population of animals, more than

WO 00/35884 PCT/EP99/10452
70% of the animals are free of emesis, preferably more than 80%, most preferably more than 90%.
A preferred class of compounds of formula (I) for use in the control of parasites in animals are those wherein;
R] is cyano or alkyl;
R2 is S(0)nR3;
R3 is alkyl or haloalkyl;
R4 is -N=C(R5)-Z-R6;
R5 is hydrogen, alkyl or haloalkyl;
ZisO, S(0)a;orNR7;
R6 and R7 are independently selected from hydrogen and unsubstituted or substituted alkyl; or
R^ and R7 may form together with the nitrogen to which they are
attached a 3 to 7 membered ring which may additionally contain one or more heteroatoms selected from oxygen, nitrogen or sulfur;X is selected from nitrogen and C-R12;
Rj 1 and Rj2 are independently selected from halogen, hydrogen, CN and NO ;
Rj3 is selected from halogen, haloalkyl, haloalkoxy, -S(0)qCF3, and -SF5;
a, n and q are independently selected from 0, 1, and 2.
Preferably Rg is alkyl which is substituted by one or more
halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, sulfide, sulfoxide, ^vifone, or phenyl or pyridyl moieties of which each phenyl or pyridyl moiety is optionally substituted with one or more groups selected from halo, nitro, and alkyl.
Preferably the method of the invention has one or more of the following features:

WO 00/35884 PCT/EP99/10452
R1 is cyano;
R4 is -N=C(R5)-Z-R6 and Z is -NR7;
X is C-R12; R] 1 and R12represent a chlorine atom; and R13 is CF3, OCF3or-SF5;
R12is-S(0)nCF3 and n is 0,1, or 2.
A further preferred class of compounds of formula (I) for use in the control of parasites in animals are those wherein:
Rl is cyano or alkyl; R4 is -N=C(R5>Z-R6; and R5 is hydrogen
or C1-C3 alkyl.
The compounds of formula (I) for use in the control of parasites in animals, preferably have one or more of the following features: R] is cyano or methyl;
R3 is halomethyl (preferably CF3);
Rl 1 and R12 each independently represent a halogen atom;
X is C-R12;
R13 is haloalkyl (preferably CF3), haloalkoxy (preferably OCF3),
or -SF5; or
n is 0, 1 or 2 (preferably 0 or 1).
A further preferred class of compounds of formula (I) for use in the control of parasites in animals are those wherein: R1 is cyano;
R2isS(0)nR3;
R3 is halomethyl;
R4 is -N=C(R5)-Z-R(s;
Z is NR7;
R5 is hydrogen or alkyl;

WO 00/35884 PCI7EP99/10452
R6 and R7 each independently represent hydrogen, alky!, alkenyl
or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR15; or
alkyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl;
X is selected from nitrogen and C-R12
R11 and R12 each independently represent a halogen atom;
R13 is selected from haloalkyl, haloalkoxy and -SF5;
R15 is alkyl or haloaikyl; and
m and n are independently selected from 0, 1, and 2. A further preferred class of compounds of formula (I) for use in the control of parasites in animals is that wherein: R1 is cyano;
R2isS(0)nCF3;
R4 is -N=C(R5)-Z-R6 or -N=C(R5)-N(R7)-R8;
Z is NR7;
R5 is hydrogen or alkyl;
R5 and R7 each independently represent hydrogen, alkyl, alkenyl
or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR15; or
methyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl;
R.g is alkcxy, haloalkoxy. aminon alkylamino. dialkylamino cr
-S(O)tR10;
' X is selected from nitrogen and C-R12;
R10 and R15 independently represent alkyl or haloalkyl;

WO 00/35884 PCT/EP99/10452
R11 and R12 each represent a chlorine-atom; R13 is CF3 or -SF5; and
m and n are 0, 1 or 2; and t is 0 or 2.
A further preferred class of compounds of formula (I) for use in the control of parasites in animals are those wherein:
R] is cyano;
R2 is S(0)nCF3;
R4 is -N=C(R5)-Z-R6;
Z is NR7;
R5 is hydrogen or methyl;
R6 and R7 each independently represent hydrogen, alkyl, alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR15; or
alkyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl;
Xis C-R12;
R11 and R12 each represent a chlorine atom:
Rj3isCF3or-SF5;
Rj5 is alkyl or haloalkyl;
m is zero, one or two; and n is 0 or 1.
A further preferred class of compounds of formula (I) for use in the control of parasites in animals are those wherein: Rj is cyano;
R2 is S(0)nCF3;
R4 is -N=C(R5)-Z-R6;
ZisNRy;

WO 00/35884 PCT/EP99/10452

R5 and R7 each represent a hydrogen atom;
R6 is alkyl or haloalkyl;
Xis C-R12;
R11 and R12 each represent a chlorine atom;
R13 is CF3 or -SF5; and
n is 0.
Compounds of formula (XX) which are preferred according 10 the present invention are those wherein: wherein: R201 is cyano;
R202 is S(O)hR203; R203 is alkyl or haloalkyl;
R204 is - N(R205)C(O)CR206R207R208;
R205 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl and halocycloalkylalkyl;
R2O6 is alkoxy, haloalkoxy, or hydrogen;
R207 and R2O8 are independently hydrogen, alkyl, or haloalkyl; or
R207 and R2O8 may form together with the carbon to which they are attached a 3 to 7 membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;
Xj is selected from nitrogen and C-R212;
R21 j and R212 are independently selected from halogen, hydrogen, CN and NO ;
and -SF ; and
5
' h and k are independently selected from 0,1, and 2.

WO 00/35884 PCT/EP99/10452
A preferred group of compounds of formula (XX) is that wherein the ring which is formed by R207 and i R-208 is interrupted by one or more heteroatoms, more preferably one oxygen atom.
The compounds of formula (I) of the present invention preferably have one or more of the following features:
R-201ls cyano;
R203 is halomethyl, preferably CF3;
R21 ] and R2J2are independently halogen;
X] isC-R2i2;
R213 is haloalkyl, haloalkoxy or -SF5; or
h is 0 or 1, or 2, preferably 0 or 1.
A preferred class of compounds that wherein R204 is
N(R205)C(O)CR206R207R208-
Another preferred class of compounds that wherein R204 is N(R205)C(O)aryl.
Another preferred class of compounds that wherein R204 1S
N(R205)C(O)OR207-
Preferably R205 is C -C alkyl, more preferably C,-C2 alkyl, most preferably methyl.
Preferably R2O6 's alkoxy, most preferably methoxy, ethoxy or propoxy.
Preferably R207 ^d R-208 are b°m hydrogen.
Among the compounds which may be used in the invention some are new and hence in another aspect of the present invention there is provided a compoundof formula (II):

WO 00/35884 PCT/EP99/10452

wherein:
R21 is cyano, alkyl, haloalkyl,, acetyl or -C(=S)NH2, C(=NOH)NH2 or C(-NNH2)NH2;
R22isS(0)mR23;
R23 is alkyl or haloalkyl;
R24 is -N=C(R25)N(R26)(R27) or -N=C(R25)-N(R27)-R2g;
R25 represents hydrogen or alkyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy or -S(O)mR35;
R26 and R27 each independently represent hydrogen, alkyl,
alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR35; or
alkyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl; wherein R35 is alkyl or haloalkyl and m is zero, one or two;
X is selected from nitrogen and C-R32;
R28 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino or -S(O),R30;
R3O is alkyl or haloalkyl;
R3 1 and R32 are independently selected from halogen, hydrogen, CN and N02;

WO 00/35884 PCT/EP99/10452
R33 is selected from halogen, haloalkyl, haloalkoxy, -S(0)rCF., and-SF5;
m and r are independently selected from 0, 1, and 2; and t is 0 or 2; with the exclusion of the compound wherein R2] is cyano; R22 is -
SCF2CH3; R25 is hydrogen; X is C-R32; R26 ^d ^27 are rnethyl; R3 ] and R32 are chlorine; and R33 is trifluoromethyl; and veterinarily acceptable salts thereof.
A further class of novel compounds of formula (II) are those wherein:
R21 is cyano or methyl;
R22isS(0)mR23; R23 is haloalkyl;
R24is-N=C(R25)N(R26)(R27);
R25 and R27 are hydrogen or unsubstituted or substituted alkyl;
R26 is haloalkyl;
X is selected from nitrogen and C-R32;
R3 ] and R32 are independently selected from halogen, hydrogen, CN and NO2;
R33 is selected from halogen, haloalkyl, haloalkoxy, -S(0)rCF ,
and -SF5;
m and r are independently selected from 0, 1, and 2; with the exclusion of the compound wherein R2] is cyano; R22 is -SCF2CH3;
R25 is hydrogen; X is C-R32; R26 a"0" R27 **£ methyl; R3 \ and R32 are chlorine; and R33 is trifluoromethyl.
A preferred class of novel compounds of formula (II) are those wherein: * R21 is cyano;
R22 is S(0)mR23;

WO 00/35884 PCT/EP99/10452
R23 is halomethyl;
R24is-N=C(R25)N(R26)(R27); R25 is hydrogen or alkyl;
R26 and R27 each independently represent hydrogen, alkyl,
alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR]5; or
alkyl substituted by phenyl or pyridyl each of which is optionally substituted with one or more groups selected from halogen, nitro and alkyl: wherein R15 is alkyl or haloalkyl and m is zero, one or two;
X is selected from nitrogen and C-R32;
R3 j and R32 each represent a chlorine atom;
R33 is selected from haloalkyl, haloalkoxy and -SF5;
m is selected from 0,1, and 2.
A further preferred class of novel compounds of formula (II) are those wherein:
R21 is cyano;
R22 is S(0)mCF3;
R24 is -N=C(R25)N(R26)(R27); or -N=C(R25)-N(R27)-R28;
R25 is hydrogen or methyl;
R26 and R27 each independently represent hydrogen, alkyl, alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mR]5; or methyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl; wherein R] 5 is alkyl or haloalkyl and m is zero, one or tv"v
R28 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino or -S(p)tR30;
X is selected from nitrogen and C-R32;

WO 00/35884 PCT/EP99/104S2

R30 is alkyl or haloalkyl;
R=and R39 each represent a chlorine atom;
R33 is CF3 or -SF5; and
m is 0, 1 or 2; and t is 0 or 2.
A more preferred class of novel compounds of formula (II) are those wherein:
R21 is cyano; R22 is(0)mCF3;
R24 is -N=C(R25)N(R26)(R27);
R25 and R27 each independently represent hydrogen or methyl;
R-26 represents hydrogen, alkyl, alkenyl or alkynyl; or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S(0)mRi5; or methyl substituted by phenyl or pyridyl which rings are optionally substituted with one or more groups selected from halogen, nitro and alkyl; wherein R15 is alkyl or haloalkyl and m is zero, one or two;
X is selected from nitrogen and C-R32;
R3 ] and R32 each represent a chlorine atom; R33 is CF3 or -SF5; and
m is 0, 1 or 2.
An especially preferred class of novel compounds of formula (II) are those wherein: R2] is cyano; R22 is S(0)mCF3;
R24 iS"' -~M;R25' (R-26A'"'27.>' R25 and R27 each represent a hydrogen atom; " R26 is alkyl or (preferably) haloalkyl; X is C-R32;

WO 00/35884 PCJ7EP99/I0452

R31 and R32 each represent a chlorine atom; R33 is CF3 or -SF5; and m is 0.
In another aspect of the present invention there is provided an compound of formula (XX) or a salt thereof as hereinbefore defined, provided that the compound is not 3-cyano-l -(2,6-dichloro-4-trifluoromethylphenyl)-5-(N-ethoxycarbonyl-N-methyl)amino-4-trifluoromethylthiopyrazole.
Most preferably, the following compounds of formula (I) and (XX) are preferred according to the present invention as listed in Tables 1 to 13. The Compound Numbers are for identification purposes only. The following symbols are hereby defined: Me means methyl; Et means ethyl; n-Pr means n-propyl; i-Pr means isopropyl; n-Bu means n-Butyl, and n-Pent means n-Pentyl; Cy means cyclopropyl.
Table 1
Compounds of formula (I) wherein R1 is cyano; R2 is SCF3; R11
is CI, X is C-Cl, R4 is -N=C(R5)ZR6, Z is NR7, R7 is H, and Rj3 is CF3 or SF5.

WO 00/35884 PCT/EP99/10452

Table 2
Compounds of formula (1) wherein Rj is cyano; K\ \ is CI; R4 is -N=C(R5)ZR6and Z is NR7

WO 00/35884 PCT/EP99/10452

Note: Compound number 232 is the acetate salt, and compound number 233 is the citrate salt.
Table 3 Compounds of formula (I) wherein R] is cyano; R11 is CI; and R4
is -N=C(R5)-N(R7)-Rg.

The following compounds of formula (XX) are preferred according to the present invention as listed in Tables 4-12.
Table 4

WO 00/358 PCT/EP99/10452

WO 00/35884 PCT/EP99/104S2
-21 -
•7^

WO 00/35884

PCT/EP99/10452

WO 00/35884 PCT/EP99/10452

WO 00/35884

PCT/EP99/10452

WO 00/35884 PCT/EP99/1045:

WO 00/35884 , PCJ7EP99/I0452
Compound 1-11 was also separated into its diastereomers, (R)l-l 1 and (S)l-11 .
Table 10 Compounds of formula (XX) wherein R201 is cyano; R204 is
5 N(R205)C(O)CR206R207R208; R207 and R208 are H; R2] ] is CI, X]
is C-Cl: and R213 is CF3 or SF5.

10 ' Table 11
Compounds of formula (XX) wherein R201 is cyano; R204 is

WO 00/35884 PCT/EP99/1045:

WO 00/35884

PCT/EP99/10452

Table 12
Compounds of formula (XX) wherein R201 is cyano; R202 is
S(O)hCF3;R204isN(R205)C(O)CR206R207R208;R211'sCl;X1 is
5 C-Cl, andR213isCF3orSF5.

WO 00/35884
-29-

Table 13 Compounds of formula (XX) wherein R2oi is cyano; R202 '■' S(0)hCF3; R204 is N(R205)C(O)aryl: R2i 1 is Cl; X] is C-Cl, R205 is CH3; and R2i3 is CF3 or SF5. Within this table the following symbols
are defined:
Ph means phenyl; Fu means furyl Th means the thiophene radical Pyr means pyridyl

WO 00/35884

PCT/EP99/1045:

WO 00/35884

PCT/EP99/10452

The present invention also relates to a composition comprising a parasiticidally effective, substantially non-emetic amount of a compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof and an acceptable carrier. Acceptable carriers for the use of the compounds are generally known to the skilled addressee concerned with pest control in animals, particularly domestic animals, most preferably dogs or cats.
The compositions which can be used in the invention can comprise generally from about 0.001 to 95% of the compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof. The remainder of the composition up to 100% comprises a carrier as well as generally various additives. In this specification and the accompanying claims, percentages are by weight.
The diluted liquid formulations generally comprise from about 0.001 to about 3% of compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof, preferably from about 0.1 to about 0.5%.
Solid formulations generally comprise from about 0.1 to about 8% of compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof .preferably from about 0.5 to about 1.5%.
Compositions for oral administration comprise one or more of the compounds of general formula (I) or salts thereof or compounds of formula (XX) or salts thereof in association with veterinarily acceptable carriers or coatings and include, for example, tablets, pills, capsules, gels, drenches, medicated feeds, medicated drinking water, medicated dietary supplements, slow-release boluses or other slow-release devices intended to be retained within the gastro-intestinal tract. Any of ihcs? may incorporate the active ingredients contained within micro-capsules or coated with acid-labile or alkali-labile or other pharmaceutically acceptable enteric coatings. Feed premixes or concentrates containing

WO 00/35884 PCT/EP99/104

compounds of the present invention for use in preparation of medicated diets, drinking water or other materials for consumption by animals may also be used. In a highly preferred embodiment, the compositions are administered postprandially, preferably from just after a meal to 2 hours after the meal.
In a highly preferred embodiment, there is provided a product which is readily chewed by the animal and which product does generally not allow human contamination when the product is provided to the animal by hand.
The compounds of general formula (I) or salts thereof or compounds of formula (XX) or salts thereof may be administered before, during or after meals The compounds of general formula (I) or salts thereof or compounds of formula (XX) or salts thereof may be mixed with a carrier and/or a foodstuff.
According to the present invention the compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof is administered orally in a dose to the animal in a dose range generally from 0.1 to 500 mg/kg of the compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof per kilogram of animal body weight (mg/kg), preferably from 1 to 100 mg/kg, more preferably from 1 to 50 mg/kg, even more preferably from 2 to 25 mg/kg, most preferably from 3 to 15 mg/kg
According to the present invention, the frequency of treatment of the animal, preferably the domestic animal to be treated by the compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof is generally from about once per week to about nnce per year, preferably from about once every two weeks to about once every six months, more preferably from about once every two weeks to once every three months, and most preferably from about once every two weeks to about once every six weeks.

WO 00/35884 PCT/EP99/J 0452
Generally the animal to be treated is adomestic animal, preferably a domesiic companion animal. More preferably the animal to be treated is a dog and/or a cat.
The compounds of the invention may be administered most advantageously with another parasiticidally effective material, such as an endoparasiticide, and/or an ectoparasiticide, and/or an endectoparasiticide. For example, such compounds include macrocyclic lactones such as avermectins or milbemycins e.g., ivermectin; pyratei (generally adminsitered as pyrantel pamoate) or an insect growth regulator such as lufenuron or methoprene.
By the term "parasites" as used in the specification and claims is meant endoparasites and ectoparasites of warm-blooded animals, particularly ectoparasites. Preferably, fleas and/or ticks are controlled by the method of the present invention.
Illustrative of specific parasites of various host animals which may be controlled by the method of this invention include arthropods such as:
Mites: Mesostigmata spp. e.g. mesostigmatids such as the chicken mite, Dermanvssus gallinae; itch or scab mites such as Sarcoptidae spp. for example Sarcoptes scabiei; mange mites such as Psoroptidae spp. including Chorioptes bovis and Psoroptes ovis; chiggers e.g. TrombicuJidae spp. for example the north american chigger, Trombicula alfreddugesi:
Ticks: e.g., soft-bodied ticks including Argasidae spp. for example Arpas spp. and Ornithodoros spp ; hard-bodied ticks including Ixodidae spp., for example Rhipicephalus sanguineus, and Boophilus spp.;
lice, e.g., Haematopinus spp., Linognathus spp. and Solenopotes spp.; „ Fleas: e.g., Ctenocephalides spp., such as dog flea (Ctenocephalides canis) and cat flea (Ctenocephalides felis); Xenopsvlla

WO 00/35884 PCT/EP99/J0452
spp. such as oriental rat flea [Xenopsvlla cheopisl: and Pulex spp. such as human flea [Pulex irritans];
True bugs: e.g., Cimicidae or including the common bed bug (Cimex lectularius);, Triatominae spp. including triatomid bugs also known as kissing bugs; for example Rhodnius prolixus and Triatoma spp.;
bloodsucking adult flies: (e.g., horn fly fHaematobia irritans], horse fly [Tabanus spp.], stable fly [Stomoxvs calcitransl. black fly [Simulium spp.], deer fly [Chrvsops spp.], louse fly [Melophagus ovinusl, tsetse fly [Glossina spp.], mosquitoes [Culex spp., Anopheles spp.. and Aedes spp.); and
parasitic fly maggots: (e.g., bot fly [Oestrus ovis and Cuterebra spp.], blow fly [Phaenicia spp.], screwworm fCochliomvia hominivorax], cattle grub [Hypoderma spp.], fleeceworm.
The present invention also relates to a use of a compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof hereinbefore described as a therapeutic agent, preferably for animals, more preferably for domestic animals.
The veterinary composition may be sterile or non-sterile. It may be a liquid (e.g. aqueous) or solid (e.g., dry) composition, in particular a freeze-dried composition, which, by addition of water or another liquid, orally effective solutions may be prepared.
The present invention also relates to a use of a compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof as hereinbefore defined for the manufacture of a veterinary composition for the control of parasites in or on an anirr.2!
The present invention also relates to a method of cleaning animals in good health comprising the application to the animal of a

WO 00/35884 PCT/EP99/10452
compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof as hereinbefore defined to the animal.
The method of cleaning an animal is not a method of treatment by therapy of the animal body per se, because
(a) the animal is in good health and requires no substantial treatment to correct a deficiency of health;
(b) the cleaning of the animal is not intended to be done by veterinary personnel, but by persons interested in the cleaning of the animal: and
(c) the purpose of such cleaning is to avoid unpleasant conditions for humans and the environment in which humans inhabit so as to not infest the said humans with arthropods carried by the animal.
By "carrier" is meant an organic or inorganic material, which can be natural or synthetic, and which is associated with the compound and which facilitates its application to the animal. This carrier is thus generally inert and should be arthropocidally acceptable. The carrier can be solid (e.g., clay, silicates, silica, resins, wax.) or liquid (e.g., water, alcohols, ketones, oil solvents, polar aprotic solvents) An example of an oil solvent is corn oil. An example of a polar aprotic solvent is dimethyl sulfoxide.
INCORPORERThe compounds of formula (II) wherein R21, R22, R24, R31, R33 and X are as defined above may be prepared from the compounds of formula (III):

WO 00/35884 PCT/EP99/I0452

(III)
wherein R21, R22' R31- R33 and X are as defined above, using processes described in European Patent Publications 0511845 or 0659745.
According to a feature of the present invention, compounds of formula (II) wherein R21. R22 R 31 R 33 and X are as defined above and R24 is -N=C(R25)-NR26R27 wherein R25 R26 and R27 are as defined above may be prepared by reacting a compound of formula (111) with a compound of formula (IV):

wherein R25, R26 and R27 are as defined above and R100 is generally an alkyl group. The reaction is optionally conducted in the presence of a catalyst such as a mineral or organic acid (for example hydrochloric acid), generally using from 1 to 100 equivalents of (IV), preferably using 1 to 10 equivalents of (IV), and is preferably conducted in an organic solvent such as tetrahydrofuran, toluene, or N,N-dimethylformamide, at a temperature of from 0°C to 150°C. Additional adjuvants such as drying agents (e.g. magnesium sulfate, potassium carbonate, or molecular sieves) may also be advantageous to the reaction. Compounds of formula (IV) are known or may be prepared by known procedures.
According to a feature of the present invetion compound of formula (II) wherein R21, R22 R1 R-33 and X are as defined above and 24 is -N=C(R25)-NR26R.27 wherein R25, R26 and R27 are as

WO 00/35884 PCT/EP99/10452
defined above, may be prepared by the reaction of a compound of formula (V):

(V) wherein R21, R22- R25' R-31-R33'X and R100 are as defined above, with a compound of formula (VI):
R27^ H
(VI) wherein R26 and R27 are as defined above. The reaction is
generally conducted using the same conditions as used for the preparation of compounds of formula (II) by the reaction of compounds of formula (III) with compounds of formula (IV).
According to a feature of the present invention, compounds of formula (II) wherein R24 is -N=C(R25)-NR27R28> ^d R2], R22' R-25> R27, R31, R33 and X are as defined above, and R28 is COR34 wherein R34 is as defined above, may be prepared by the reaction of the corresponding compounds of formula (II) wherein R24 is -N=C(R25)-xiR-nH with an acid chloride of formula (VIP:
R34COCI (VII) •- wherein R34 is as defined above. The reaction is generally performed in the presence of a base such as a trialkvlamine for example

WO 00/35884 PCT/EP99/10452

triethylamine in a solvent such as dichlororriethane, at a temperature of from 0°C to 50°C
According to a feature of the present invention, compounds of formula (II) wherein R24 is -N=C(R25)-NR27R28, an(^ R21- R22>R25-R27. R31, R33 and X are as defined above and Rog is -S(O)tR30 may
be prepared by the reaction of the corresponding compound of formula (11) wherein R24 is -N=C(R25)-NR27H with a sulfonyl chloride or a
sulfenyl chloride of formula (VIII):
R30S(O)tCl (VIII)
The reaction is generally performed in the presence of a weak base such as a trialkylamine for example triethylamine, or pyridine in a solvent such as dichloromethane, at a temperature of from 0°C to 50°C.
Compounds of formula (VI), (VII) and (VIII) are known or may be prepared by known procedures.
Compounds of formula (III) and (V) may be generally prepared according to known processes, for example as described in International Patent Publications WO 87/3781, WO 93/6089, WO 94/21606 WO 97/07102, WO 98/24767,, WO 98/28277, WO 98/28278 and WO 98/28279,, European Patent Application 295117, 846686, and United States Patent 5232940..
In another aspect of the present invention, compounds of formula (XX) wherein R204 is -N(R205)C(O)CR206R207R208> N(RvuvC(G)aryi, or N(R205)C(G')OR207 ^ generally prepared from compounds of formula (XXI):

WO 00/35884

PCT/EP99/J0452

respectively by reaction with halides of formulae X2C(O)CR206R207R208> X2C(0)aryl, or X2C(O)OR207, wherein R201> R202> R205> R206' R207> R208> R21 ]. R213> and xl are defined above and wherein X2 is a halogen atom. The reaction is generally carried ouT in the presence of a base, generally using from 1 to 10 molar equivalents of the halide, and is preferably conducted in the presence of an organic solvent such as tetrahydrofuran, methylene chloride, at a temperature of from 0°C to 150°C.
Compounds of formula (XXI) may be prepared from a compound of formula (XXII):

WO 00/35884 PCT/EP99/10452
.
(XXII) : by reaction with a compound of formula (XXIII):
X2R205(XXIII) wherein R201, R202. R205, R211, R213, XI and X2 are defined above. Compounds of formula (XXIII) are generally known in the art as alkylhalides or substituted alkylhalides. Compounds of formula XX11 may be prepared by methods described in International Patent Publications WO 87/3781, WO 93/6089, WO 94/21606, WO 97/07102, WO 98/24767,, WO 98/28277, WO 98/28278 and WO 98/28279, European Patent Application 295117, 659745, 846686, and United States Patent 5232940 or other methods known to the person skilled in the art.
Alternatively compounds of formula (XXI) may be prepared by reduction of compounds of formula (XXIV):

(XXIV) wherein k 201R 202,R211 R213 and X1 are defined above. The reduction generally is effected by the use of a standard hydride ion donor, for example sodium borohydride or sodium cyanoborohydride. The reaction is generally effected in an polar solvent such as ethanol or

WO 00/35884 PCT7EP99/10452

methanol and generally using from 1 to 10 molar equivalents of the hydride, and is preferably conducted at temperature of from -100°C to 150°C.
Compounds of formula (XXIV) may be prepared using methods described in EP 295117, WO 97/22593 or other methods known to those skilled in the art.
In another aspect of the invention there are provided the compounds 3-Cyano-1 -(2,6-dichloro-4-trifluoromethylphenyl)-5-ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole and 3-cyano-1 -(2,6-dichloro-4-trifluoromethylphenyl)-5-rnefhylarnino-4-trifluoromethylsulfinylpyrazole which are useful intermediates for the preparation of compounds for use according to the present invention.
Biological Example
Compounds 1-1, 2-1, 3-1,4-1, 11-1, 13-1, 28-1, 31-1, 32-1, 36-1, 37-1,38-1, 1-3,2-3,3-3.4-3,6-3,41-3, 1-5,2-5,3-5,6-5, 11-5,27-5, 28-5, 1-7,3-7,5-7, 1-9, 1-11,6-11,7-11, 1-12, 11-12,13-12,67-1,68-1, 69-1, 70-1, 72-1, 75-1, 76-1, 77-1, 78-1, 79-1, 80-1, 81-1, 82-1, 115-1, 116-1, 117-1,118-1, 119-1, 120-1, 121-1, 122-1,123-1,124-1,211-1, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, R3-3, S3-3, Rl-7, Sl-7, (R,S)l-9, (R,R)l-9, (S,R)l-9, (S,S) 1-9, S1-11.R1-11, 126-1, 127-1 and 130-1 were formulated as a 30 mg/mL formulations in a 1:1 volume/volume solution of dimethyl sulfoxide and corn oil Using this formulation, mixed breed dogs and cats were treated at a rate of 10 me of the compond per kg(mg/kg)of hoHv weight of the dog and 20 mg/kg of the cat treated. The animals were fasted for at least 8 hours prior to treatment, fed half of the daily ration

WO 00/35884 PCT/EP99/10452
immediately prior to treatment, then allowed access to the remainder of the daily ration immediately following treatment.
All dogs were infested with cat fleas (Ctenocephalides felis) and with ticks (Rhipicephalus sanguineus) 1 day prior to administration of the compound. Cats were only infested with fleas. The initial flea and tick counts were performed 1 day after the administration of the compounds. At 7, 14, 21 and 28 days after treatment the dogs were re-infested with ticks and 8, 15, 22 and 29 days after treatment the dogs and cats were re-infested with fleas. At 1, 9, ) 6, 23 and 30 days after treatment the control of fleas and ticks in treated dogs and cats was determined versus a group of infested dogs and cats which received a placebo consisting of a 1:1 volume/volume solution of dimethyl sulfoxide and corn oil. To determine the efficacies of the compounds, the arthropods were combed from the animals and counted.
In the animals treated with the compounds above, there was substantially no emesis after 2, 8 and 24 hours. Generally long-term control of fleas and ticks was provided in dogs. In the cats treated, there was commercially acceptable control of fleas for at least one day post treatment.
The results of this example were superior to those obtained with compounds of the prior art, for example, fipronil.
The following non-limiting Synthesis Examples illustrate the preparation of compounds of formula (I) and the Reference Examples illustrate the preparation of intermediates used in their synthesis.
Synthesis Example 1
A solution of 5-amino-3-cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylthiopyrazole (1 g) inN.N-
dimefhylformamide dimethyl acetal was heated at 50PC for 1 hour.

i

WO 00/35884

PCT/EP99/10452

Evaporation of solvents gave 3-cyano-} -(2,6-dichloro-A-trifluoromeihylphenyO-S-N'-dimethylaminomethylideneamino^-uifluoromethylthiopyrazole m.p.l41°C.
By proceeding in a similar manner the following compounds were also prepared:
3-cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5-N'-dimethylarrunomethylideneamino-4-trifluoromethylsulfonylpyrazole m.p.209°C; and
3-cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5-N'-dimethylaminomethylideneamino-4-trifluoromethylsulfinylpyrazole m.p.207°C.
Synthesis Example 2
A solution of 3-cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5-ethoxymethylideneamino-4-trifluoromethylthiopyrazole (5 g) in ethanol was treated with benzylamine (11.4 ml), stirred overnight, evaporated and purified by reverse-phase column chromatography (C-18 stationary phase column, eluting with MeOH/water) to give 5-N'-benzylaminomethylidenearnino-3-cyano-1 -(2,6-dichloro-4-trifluoromethylphenyl)- 4-trifluoromethylthiopyrazole 1.18 g), m.p.l 13°C.
By proceeding in a similar manner the compounds of formula (II) wherein R2j is CN; R24 is -N=CH-NHR26; ^31 is CI; X is C-Cl; and R33 is CF3 shown in Table 4 were also prepared.
Table 4

Compd No. R22 R26 M.P.°C
?l SCR CH2CN 175
211-1 SCF3 CH2CF3 130
222 SCF3 CH3 173
223 SOCF3 CH2Ph 173
225 SOCF3 CH3 144
226 SOCF3 CH3 144

WO 00/35884 PCT/E P99/10452

1227 SOCF3 CH2CF3 175
228 S02CF3 2-propynyl 149
229 S02CF3 CH2Ph 182
230 S02CF3 CH2CF3 183
209-1 SCF3 iPr
207-1 SCF3 CH2CH3 141
Reference Example 1
A solution of 5-amino-3-cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylthiopyrazole (500 g) in methyl orthoformate was treated with concentrated hydrochloric acid (10 ml) and heated at 50oC After 8 hours the reaction mixture was evaporated to give a solid which was washed (heptane) and air-dried to give 3-cyano-1 -(2,6-dichloro-4-trifluorornethylphenyl)-5-ethoxymeihylideneamino-4-trifluorornethylthiopyrazole (217 g), m.p. 68°C.
By proceeding in a similar manner the following intermediates were also prepared:
3-cyano-1 -(2.6-dichloro-4-trifluoromethylphenyl)-5-ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole, m.p.63°C; and 3-cyano-1 -(2,6-dichloro-4-trifluoromethylphenyl)-5-ethoxymethyIideneamino-4-trifluoromethyIsulfonylpyrazole, m.p.118oC
Synthesis Example 3
3-Cyano-1 -(2,6-dichIoro-4-trifluoromethylphenyl)-5- mctH>i^i)iiiu-4-uintioromethyisuifrnyipyra2oie (111.55 g, 0.247 moles), triethylamine (62.45 g, 0.618 moles), 4-dimethylaminopyridine (3 g, 0.0247 moles), and tetrahydrofuran (700 ml) was combined. The resulting solution was heated to 45°C and ethoxyacetyl chloride (45.2 g,

WO 00/35884 PCT/EP99/10452
0.37 mmol) was added dropwise over 10 min. After 1 h. the mixture was evaporated to a brown residue, which was dissolved in 500 ml of ethyl acetate and washed with 2 x 300 ml of water. The organic phase was dried over magnesium sulfate, filtered, and evaporated to a brown oil. The oil was triturated with 1 L of hot cyclohexane. The resulting solids were collected by filtration and washed with 500 ml of hoi cyclohexane, then air dried to afford of compound 3-3 as a beige powder (116.7 g). Evaporation of the mother liquors afforded a second crop of compound 3-3 (8.4 g).
In a similar fashion or by modifications according to methods known to the skilled addressee, the following compounds were prepared. The compound numbers in the left column refer to the Tables cited above.

Compound Number Mass Spectral molecular ion + 1 (M+l)
1-1 477
2-1 507
3-1 521
4-1 535

11-1 505

13-1 549
28-1 537
31-1 517
32-1 531
36-1 535

37-1 521
38-1 535
1-3 593
2-3 523

WO 00/35884

PCT/EP99/10452

WO 00/35884

PCT/EP99/10452

Reference Example 2:
Step A: Preparation of 3-Cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5~ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole.
A 12-L inrec-neeked nask. titled with an uverhcau simcr, heating mantle, water separaior (e.g. Dean Stark trap) with condenser was placed under a nitrogen atmosphere and charged with 1.475 kg (3.37 moles) of fipronil and 6 L of triethyl orthoformate. The suspension was

WO 00/35884 PCT7EP99/10452
heated to reflux over 2.5 h, then at reflux for 3 h with collection and removal of the distillate. The mixture was cooled to room temperature, then evaporated under reduced pressure at a bath temperature of 60-80°C, then at 50°C overnight. The resulting beige solid, 1.717 kg (95.8 % by HPLC, 3.335 moles, 99% purity corrected yield) was used without further purification, (m.p. about 63°C)
Step B: Preparation of 3-Cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5-methylamino-4-trifluoromethylsulfinylpyrazole.
A 50 L reactor was charged with 3-Cyano-l-(2,6-dichloro-4-trifluoromethyIphenyl)-5-ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole (1.645 g, 3.335 moles) and absolute ethanol (16 L) under nitrogen. The solution was cooled to 10°C, and sodium borohydride (266 g, 7.03 moles) was added slowly such that the temperature, remained generally below 35°C. After 6.75 h, some additional sodium borohydride (25 g, 0.66 moles) was added and stirring was continued overnight. Acetic acid (1.3 L, 22.7 moles) was added to quench, followed by 16 L of water. The resulting precipitate was collected by filtration, washed with water, and air-dried. Recrystallization from methanol afforded 3-Cyano-l-(2,6-dichloro-4-trifluoromethylphenyl)-5-rnethylamino-4-
trifluoromethylsulfinylpyrazole (350 g) as an off-white solid, (m.p. about 227OC

WE CLAIM:
1. A 1 -arylpyrazole of formula (XX):

(XX) Wherein:
R201 is cyano;
R202 is S(O)hR203;
R203 is alkyl or haloalkyl;
R204 is —N(R205)C(O)CR206 R207 R208;
R205 is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, cycloalkylalkyl or halocycloalkylalkyl;
R206 is alkoxy, haloalkoxy, alkoxyalkyl or haloalkoxy-alkyl;
R207 and R208 are each hydrogen;
Xi is nitrogen or C-R212;
R211 and R212are, independently, halogen, hydrogen, CN or NO2;
R213 is halogen, haloalkyl, haloalkoxy, -S(0)kCF3, or -SF5; and
h and k are, independently, 0, 1 or 2;
or a veterinarily acceptable salt thereof.
2. A composition comprising a parasiticidally effective substantially non-emetic amount from 0.001 to 95% of a compound as claimed in claim 1, or a veterinarily acceptable salt thereof, and a veterinarily acceptable carrier therefor.
Dated this on 25th May, 2001
[Dr. Anushri Gupta]
of REMFRY & SAGAR
Attorney for the Applicants

Documents:

in-pct-2001-00592-mum-cancelled pages(25-5-2001).pdf

in-pct-2001-00592-mum-claims(granted)-(25-5-2001).doc

in-pct-2001-00592-mum-claims(granted)-(25-5-2001).pdf

in-pct-2001-00592-mum-correspondence(30-11-2007).pdf

in-pct-2001-00592-mum-correspondence(ipo)-(1-11-2007).pdf

in-pct-2001-00592-mum-form 1(25-5-2001).pdf

in-pct-2001-00592-mum-form 13(14-8-2007).pdf

in-pct-2001-00592-mum-form 18(28-12-2005).pdf

in-pct-2001-00592-mum-form 2 (granted)-(25-5-2001).doc

in-pct-2001-00592-mum-form 2(granted)-(25-5-2001).pdf

in-pct-2001-00592-mum-form 3(13-8-2007).pdf

in-pct-2001-00592-mum-form 3(25-5-2001).pdf

in-pct-2001-00592-mum-form 5(25-5-2001).pdf

in-pct-2001-00592-mum-form-pct-ipea-409(25-5-2001).pdf

in-pct-2001-00592-mum-form-pct-isa-210(25-5-2001).pdf

in-pct-2001-00592-mum-petition under rule 137(14-8-2007).pdf

in-pct-2001-00592-mum-petition under rule 138(14-8-2007).pdf

in-pct-2001-00592-mum-power of authority(13-8-2007).pdf

« Previous Patent

Next Patent »

Patent Number

214052

Indian Patent Application Number

IN/PCT/2001/00592/MUM

PG Journal Number

24/2008

Publication Date

13-Jun-2008

Grant Date

25-Jan-2008

Date of Filing

25-May-2001

Name of Patentee

AVENTIS CROPSCIENCE S.A.,

Applicant Address

55 AVENUE RENE CASSIN, F-69006 LYON, FRANCE.

Inventors:

#	Inventor's Name	Inventor's Address
1	YVES RIBEILL	313 MEETINGHOUSE CIRCLE, RALEIGH, NC 27609, USA.
2	SCOT KEVIN HUBER	6104 BRAMBLEWOOD DRIVE, RALEIGH, NC27612, USA
3	SUSAN MARIE McCOMB	110 ARROWHEAD WAY, CARY, NC 27513, USA
4	MICHAEL JAMES MALASKA	3228 GALT WAY, CHAPEL HILL, NC 27516, USA
5	DAVID CHOU	400 DUNWOODY DRIVE, RALEIGH, NC 27615, USA
6	ADALBERTO PEREZ DE LEON	716 SARRATT RIDGE COURT, WAKE FOREST, NC 27587, USA

PCT International Classification Number

C07D 231/44

PCT International Application Number

PCT/EP99/10452

PCT International Filing date

1999-12-10

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	60/111,857	1998-12-11	U.S.A.
2	60/140,680	1999-06-24	U.S.A.